Research programme: therapeutics - Sanofi-aventis/Harvard University
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Harvard University; sanofi-aventis
- Developer Harvard University
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA